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Asthma
'' Asthma is a disease characterized by an
increased responsiveness of the trachea and
bronchi to various stimuli and manifested by a
wi despread narrowing of the airways that
changes in severity either spontaneously or in
response to therapy ." 1 The airway narrowing is
the end result of some combination of bronchial
muscle contraction, tissue inflammation , mucosa! edema, and luminal occlusion by cellular
debris and thickened secretions. During the last
decade, basic and applied research has shed
light on the physiology of the above changes
and has led to breakthroughs in therapy and the
more rational use of older and newer therapeutic agents , both separately and together.
Anatomy
The nasal passages , the oropharynx , and
the large , and some smaller, bronchi are extensively provided with a variety of receptors which
respond to temperature and irritating stimuli of
many types. The sensory signals emanating
from these receptors and others are transported
to the central nervous system by the vagus
nerve . The motor innervation of the bronchi is
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via the vagus (cholinergic) and sympathetic
trunks (adrenergic} , both of which affect bronchomotor tone and secretions .
The epithelium of the intrathoracic airways
is covered with a "mucociliary blanket" which
facilitates the removal of particulate material ;
mucus is secreted by glandular epithelial cells .
Ciliated epithelium constantly moves the mucus
layer from peripheral to central airways , where
cough and expectoration eliminate the trapped
particles from the respiratory tract.
The multiple branch ing airways of the
lung, as far distal as the respiratory bronchiole,
are surrounded by bands of smooth muscle.
Proportionately greater amounts of muscle are
present in small bronchioles relative to large
and medium bronchi , and constriction of this
musculature can virtually occlude the airway .
Physiology
For any given flow rate, airways resistance
is dependent on the cross-sectional area
through which the gas is flowing, that is, the
larger the cross-sectional area the less the resistance and vice versa . Bronchial smooth muscle
contraction can markedly increase resistance
and this can be augmented by compromise of
the airway 's lumen by secretions, cells, and
other factors . Stimulation of the vagus nerve inMCV QUARTERLY 15(3):75-78, 1979 /
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duces bronchial smooth muscle contraction and
increases mucus secretion ; sympathetic nerve
stimulation has a minimal opposite effect.
The relative "tone " of bronchial smooth
muscle, that is, the balance between muscle
contraction and relaxation , is controlled by the
intracellular ratio of the cyclic nucleotides. High
levels of cyclic adenosine monophosphate
(cAMP) , induce relaxation, and conversely, increased levels of cycl ic guanos ine monophosphate (cGMP) , induce contraction . Beta
agonists (isoproterenol, ephedrine, terbutaline ,
among other drugs) appear to increase levels of
cAMP by stimulation of the enzyme adenylcyclase; corticosteroids may work in this fashion
as well. Methylxanthines, such as theophylline,
appear to prevent the breakdown of cAMP by
the enzyme phosphodiesterase and thus increase intracellular cAMP levels. Vagal stimulation in turn stimulates cAMP production, causing bronchoconstriction .2

Pathophysiology
A large population of mast cells containing a variety of preformed "mediators" of hypersensitivity such as histamine are normally
found in the pulmonary interstitium; these cells
can synthesize from precursors other mediators
such as a slow-reacting substance of ananphylaxis (SRS-A). Both of these substances are
powerful bronchoconstrictors and may increase
cell membrane permeability, leading to mucosa!
edema . Additionally, these mediators increase
bronchial receptor sensitivity thus enhancing
neurogenic-induced bronchoconstriction. Other
mediators can cause inflammatory changes in
bronchi and attract and activate phagocytic
cells .
In extrinsic (allergic) asthma , mast cells
are sensitized by the attachment of antigen-specific lgE to their surface . If an appropriate antigen, such as pollen, fixes to the lgE, the various
mediators are released and/ or synthesized. 3
The rate of release/synthesis of mediators is
governed by the cAMP /cGMP ratio in the mastI
cell , and is thus subject to pharmacologic manipulation as has been discussed .
In other types of asthma (adult onset, intrinsic, aspirin-induced , and other forms) immunologic mechanisms do not play a dominant
role. Some suggested mechanisms causing the
airway hyperreactivity in these types of asthma
are:
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B-adrenergic blockade: A decreased response to beta agonist drugs has been noted
in many asthmatics. It is possible that either
congenital defects in adenylcyclase production
or recurrent infections could induce this blockade .
Cholinergic dominance: This hypothesis
presupposes that the vagus nerve in the asthmatic is easily stimulated via the irritant receptors, leading to an enhanced bronchoconstrictive response (the ''twitchy vagus '' theory).
Cortical (emotional) components may act via
this pathway. Whether the vagus hyperreactivity
is a primary or secondary defect is in question .
Histamine , for example, increases irritant-receptor sensitivity and indirectly plays a role in vagally mediated bronchoconstriction .
Adrenergic amine deficiency: This hypothesis presupposes that in response to bronchoconstrictive stimul i, the adrenal medulla should
release additional epinephrine to partially modify this response (epinephrine acting as a beta
agonist) . In the asthmatic , this response is impaired .
Smooth muscle abnormalities: Asthmatics
are known to have hypertrophied bronchial
musculature. Whether or not the muscle is also
innately more reactive is undecided .
Alpha-adrenergic hyperresponsiveness:
Some asthmatics have been shown to have an
exaggerated response to phenylephrine (a pure
alpha agonist) in organs other than the lung. It is
thus hypothesized that naturally occurring alpha
agonists (which increase mast cell and bronchial musculature intracellular cGMP) can induce bronchoconstriction .
Much is still to be learned about asthma.
Apparently, in all individuals, many factors play
a role in the pathogenesis of the disease, some
factors being dominant and others seeming less
significant. It is the clinician's responsibility to
determine in his patient which factors predominate and to tailor the treatment to these
findings.

Chronic Obstructive Pulmonary Disease
(COPD}
Emphysema and bronchitis constitute the
major disease entities which fall under the heading of Chronic Obstructive Pulmonary Disease
(COPD) . Although emphysema and bronchitis
will , for discussion purposes , be considered
separately , they occur concomitantly in most
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patients with COPD. Only a small percentage of
pa tients will have ''pure'' emphysema or
" pure " bronchitis.

"Class.ic" Findings in Far-Advanced Emphysema and Bronchitis
Emphysema is defined as destruction of
terminal alveolar capillary units with enlargement of the remaining air spaces. Etiologically,
it is causally related to cigarette smoking and
certain genetic disorders such as alpha 1 antitrypsin deficiency. In addition , there is some evidence that recurrent childhood pulmonary infections predispose smokers to emphysema.
The typical patient with far-advanced emphysema is 45 to 50 years of age and complai ns of dyspnea on mild exertion . Unless an
associated bronchitis is present, cough and
sputum production do not occur. Physical examination reveals a thin, cachectic patient with
an increased respiratory rate , using his or her
accessory muscles of respiration, an increase in
anteroposterior chest diameter, a tympanitic
chest percussion note, and decreased breath
sounds. Laboratory results are unremarkable
and the chest radiograph shows a vertical,
small heart with clear , hyperinflated lung fields;
· th e EKG shows low voltage. Pulmonary function
tests are consistent with hyperinflation, decreased flow rates and diffusing capacity and
airway collapse . Mild hypoxemia (Pa0 2 > 55
torr) and normocapnea (PaC0 2 < 45 torr) are
common findings . Because of the labored
breathing and lack of cyanosis this type of patient has been termed the " pink puffer." As
lung destruction is the basic problem, most
therapeutic interventions are nonrewarding, but
teaching the patient to purse-lip breathe may
lessen the dyspnea and decrease the respiratory rate. 1
Chronic bronchitis is defined as an incre ase in sputum production two to three
months out of the year for two years in a row.
Patients with this condition usually are cigarette
smokers and/or have been exposed to industrial or air pollutants . Their chief complaint is a
cough productive of sputum , often described as
"a cigarette or morning cough ." The bronchitic
patient shows no evidence of weight loss , has a
normal chest AP diameter but may have, on
auscultation , wheezes , rhonchi , and early inspiratory rales . In addition, signs of right ventricular failure (jugular venous distention, hepa-
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Fig-Decreases in FEV 1 with age in nonsmokers, nonsusceptible smokers and susceptible smokers. This graph
depicts fall in FEV 1 in one particular susceptible smoker.
Other smokers will have different FEV 1 loss rates thus
reaching the " disability" line at different ages. See text for
explanation <i!nd discussion .

tomegaly, and peripheral edema) may be
present. Polycythemia and, in certain cases, either sputum or blood eosinophilia may be found
on routine laboratory analysis. Carbon dioxide
retention (PaC0 2 > 45 torr) and hypoxemia
(Pa0 2 < 55 torr) are found on arterial blood gas
analysis; pulmonary function tests reveal decreased flow rates which may respond to
bronchodilators. Chest radiography shows an
enlarged heart (mainly right ventricle) with increased bibasilar lung markings; the EKG may
show right ventricular hypertrophy. Because of
the cyanosis and the peripheral edema, these
patients have been termed "blue bloaters."
Treatment consists of antibiotics for recurrent
pulmonary infections, diuretics and digitalis for
the right heart failure and supplemental oxygen
for the hypoxemia.

Which Patients are at Risk of Developing
Symptomatic COPD?
The patient with far-advanced COPD responds poorly to treatment and the average life
expectancy after severe symptoms ensue is
3 % to 5 years. 2 It would be advantageous to
predict which patients who smoke may develop
far-advanced disease as it is now known that ·
90% to 95% of all smokers are either not susceptible or minimally susceptible to the effect of
cigarette smoke; that is, life-long smoking does
not lead to symptomatic lung disease as described above. Most cigarette smokers have
normal or near normal FEV 1 s compared to age-
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matched nonsmoking controls (Line A, Figure). 3
A small percentage of patients, however, may
be susceptible to cigarette smoke and if FEV 1 s
are performed yearly (after age 40), there will
be a marked decline in the FEV, per year (Line
B, Figure) compared to normal values (Line A,
Figure). If these patients continue to smoke,
they will become symptomatic and disabled at a
relatively early age; if they stop smoking, the
FEV, decline will slow (Line C, Figure), but impaired pulmonary functions may be demonstrable, although the patient may be asymptomatic. If smoking is stopped late in the course
of the disease (that is, by the time disability occurs), although the FEV 1 decline will improve,
death will ensue in a relatively short period of
time (Line D, Figure). Therefore, FEV 1 s should
be performed yearly in all cigarette smokers >
40 years of age. If a marked loss of FEV 1 occurs (> 60 to 70cc/sec/yr), an aggressive approach to cessation of smoking should be instituted.
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The Figure is modified by permission from the British
Medical Journal ,(1 : 1645-1648, 1977).
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